Pfizer

Québec invests in public-private partnership for personalized cancer medicine

Wednesday, February 20, 2013 10:55 AM

The Québec government has invested $10 million in the Personalized Medicine Partnership for Cancer (PMPC), a public-private partnership focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients.

More... »

Dako, Pfizer collaborate on companion diagnostics

Thursday, February 14, 2013 08:00 AM

Dako, a tissue-based cancer diagnostics company based in Denmark, has entered into a collaboration agreement with Pfizer in the field of companion diagnostics.

More... »

Labrys Biologics secures $31M financing, acquires antibody for chronic migraine from Pfizer

Friday, January 4, 2013 11:57 AM

Labrys Biologics, a development stage biotechnology company focused on chronic migraines, has completed a $31 million Series A financing from four leading venture capital firms: venBio, Canaan Partners, InterWest Partners and Sofinnova Ventures. With the close of the financing, Labrys has acquired RN-307 from Pfizer Inc., a phase II ready anti-CGRP humanized monoclonal antibody for the treatment of chronic migraine. In addition, Steven P. James has been appointed president and CEO.

More... »

Repligen, Pfizer form licensing agreement for spinal muscular atrophy program

Friday, January 4, 2013 11:29 AM

Repligen, a life sciences company based in Waltham, Mass., has entered into an exclusive worldwide licensing agreement with global pharmaceutical company Pfizer to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

More... »

FDA approves Eliquis to reduce blood clots non-valvular atrial fibrillation

Wednesday, January 2, 2013 02:48 PM

The FDA has approved Bristol-Myers Squibb and Pfizer’s anti-clotting drug Eliquis (apixaban), an oral tablet used to reduce the risk of stroke and dangerous blood clots in patients with atrial fibrillation that is not caused by a heart valve problem.

More... »

Pfizer acquires NextWave Pharmaceuticals

Thursday, November 29, 2012 01:49 PM

Pfizer has completed its acquisition of NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

More... »

NEOMED Institute aims to renew biopharmaceutical research in Québec

Tuesday, November 27, 2012 11:33 AM

AstraZeneca Canada and Pfizer Canada are forming a partnership with the Québec government to create the NEOMED Institute, a new kind of life sciences research center. A total of $100 million will be invested to establish and support the research center over five years.

More... »

CFFT, Pfizer expand collaboration on cystic fibrosis by $58M

Monday, November 19, 2012 02:46 PM

Cystic Fibrosis Foundation Therapeutics (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, has expanded its research collaboration with Pfizer designed to discover new drugs to treat people with the most common mutation of cystic fibrosis (CF), Delta F508.

More... »

Ziarco founded with Series A financing

Monday, November 5, 2012 11:01 AM

Recently founded Ziarco, a clinical-stage biotech focused on therapeutics targeting inflammatory and allergic diseases, has closed an initial $6 million tranche of Series A financing totaling $27 million. The round was led by Biotechnology Value Fund, with participation by Pfizer Venture Investments.

More... »

Portola, BMS, Pfizer ink collaboration on study on reversing anticoagulation

Friday, November 2, 2012 01:57 PM

Portola Pharmaceuticals, a therapeutics company focused on thrombosis, inflammatory disease and cancer, global biopharmaceutical company Bristol-Myers Squibb (BMS) and Pfizer have signed a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor Elquis (apixaban).

More... »